Abstract
Hyperhomocysteinemia is a risk factor for a number of neurodegenerative and cardiovascular diseases. We have shown that homocysteine induces excitotoxic effects in cells expressing glutamate receptors of the NMDA class. These receptors were found not only in neurons but also in immune-competent cells, neutrophils, red blood cells, cardiomyocytes, and osteoblasts. Activation of these cells by homocysteine results in an increase in cytoplasmic calcium ions, accumulation of reactive oxygen species, and activation of MAP kinase. An overload of immune-competent cells activates both necrotic and apoptotic cell death, whereas the neuropeptide carnosine (an antioxidant and immune modulator) protects cells against both processes. In a model of prenatal hyperhomocysteinemia in rats, we have found that carnosine protects animals against homocysteine toxicity with no change of the blood homocysteine levels. The efficiency of carnosine has also been demonstrated in clinical trials of chronic brain ischemia and Parkinson’s disease.
Keywords: Homocysteine, homocysteic acid, NMDA receptors, neurons, immune competent cells, carnosine.
Current Aging Science
Title:Why Is Homocysteine Toxic for the Nervous and Immune Systems?
Volume: 6 Issue: 1
Author(s): Alexander Boldyrev, Ekaterina Bryushkova, Anna Mashkina and Elizaveta Vladychenskaya
Affiliation:
Keywords: Homocysteine, homocysteic acid, NMDA receptors, neurons, immune competent cells, carnosine.
Abstract: Hyperhomocysteinemia is a risk factor for a number of neurodegenerative and cardiovascular diseases. We have shown that homocysteine induces excitotoxic effects in cells expressing glutamate receptors of the NMDA class. These receptors were found not only in neurons but also in immune-competent cells, neutrophils, red blood cells, cardiomyocytes, and osteoblasts. Activation of these cells by homocysteine results in an increase in cytoplasmic calcium ions, accumulation of reactive oxygen species, and activation of MAP kinase. An overload of immune-competent cells activates both necrotic and apoptotic cell death, whereas the neuropeptide carnosine (an antioxidant and immune modulator) protects cells against both processes. In a model of prenatal hyperhomocysteinemia in rats, we have found that carnosine protects animals against homocysteine toxicity with no change of the blood homocysteine levels. The efficiency of carnosine has also been demonstrated in clinical trials of chronic brain ischemia and Parkinson’s disease.
Export Options
About this article
Cite this article as:
Boldyrev Alexander, Bryushkova Ekaterina, Mashkina Anna and Vladychenskaya Elizaveta, Why Is Homocysteine Toxic for the Nervous and Immune Systems?, Current Aging Science 2013; 6 (1) . https://dx.doi.org/10.2174/18746098112059990007
DOI https://dx.doi.org/10.2174/18746098112059990007 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Functions of MAPR (Membrane-Associated Progesterone Receptor) Family Members As Heme/Steroid-Binding Proteins
Current Protein & Peptide Science Molecular Pathophysiology of Cavernous Nerve Injury and Identification of Strategies for Nerve Function Recovery After Radical Prostatectomy
Current Drug Targets A Valuable Animal Model of Spinal Cord Injury to Study Motor Dysfunctions, Comorbid Conditions, and Aging Associated Diseases
Current Pharmaceutical Design Targeting Heme Oxygenase-1 for Neuroprotection and Neuroinflammation in Neurodegenerative Diseases
Current Drug Targets Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review
Current Pharmaceutical Biotechnology Biologically Active Peptides Interacting with the G Protein-Coupled Formylpeptide Receptors
Protein & Peptide Letters Nerve Growth Factor and Brain-Derived Neurotrophic Factor in Schizophrenia and Depression: Findings in Humans, and Animal Models
Current Neuropharmacology Multilevel Analysis of Locomotion in Immature Preparations Suggests Innovative Strategies to Reactivate Stepping after Spinal Cord Injury
Current Pharmaceutical Design Causal Mechanisms Underlying Periventricular Leukomalacia and Cerebral Palsy
Current Pediatric Reviews Current Update on Synopsis of miRNA Dysregulation in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Biological Responses to Hydrogen Molecule and its Preventive Effects on Inflammatory Diseases
Current Pharmaceutical Design New Perspectives in the Pharmacological Potential of Naringin in Medicine
Current Medicinal Chemistry Adverse Drug Reactions in the Oral Cavity
Current Pharmaceutical Design Recent Advances on Patient Transferring Device
Recent Patents on Mechanical Engineering Clinical Improvement and Cortical Adaptations After Functional Electrical Stimulation in Parkinson’s Disease Patients
CNS & Neurological Disorders - Drug Targets Molecular Mechanisms and Therapeutic Application of NSAIDs and Derived Compounds in Alzheimers Disease
Current Alzheimer Research Basic Pharmacology of NMDA Receptors
Current Pharmaceutical Design Current Concepts in Reprogramming Somatic Cells to Pluripotent State
Current Stem Cell Research & Therapy Patent Annotations
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) From Antidepressant Drugs to Beta-Mimetics: Preclinical Insights on Potential New Treatments for Neuropathic Pain
Recent Patents on CNS Drug Discovery (Discontinued)